日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / State Council News

Nation issues new anti-monopoly guidelines for pharma sector

By Li Jiaying | chinadaily.com.cn | Updated: 2025-01-24 21:04
Share
Share - WeChat
Pharmacists dispense drugs at a hospital in Huzhou, Zhejiang province, in August. YI FAN/FOR CHINA DAILY

In an effort to safeguard fair market competition and protect consumer interests, the State Council's anti-monopoly commission officially issued new anti-monopoly guidelines on Friday targeting the pharmaceutical sector. 

A key highlight of the guidelines lies in the involvement of online platforms' monopolistic regulations. Given the rapid growth of online medical consultations and pharmaceutical e-commerce, the guidelines, for the first time, incorporate measures to address monopolistic practices in online medicine businesses, prohibiting platforms from engaging in the misuse of data, algorithms or platform rules.

The broad scope of the new guidelines also merits attention, which encompasses the entire pharmaceutical product chain — including traditional Chinese medicine, chemical drugs and biological products — compared to the previous version, which was largely concentrated in the limited realm of chemical active pharmaceutical ingredients (APIs).

"The pharmaceutical industry is highly technology-driven. Besides APIs, it also includes innovative drugs, patented medicines and generics. Every stage — from procurement and R&D to production, distribution and generic development — involves significant technological advancements and related protective strategies," said Zhou Wei, deputy director of the health law research center at Wuhan University, in an earlier interview. 

To further combat "false innovation", the guidelines also address a new type of patent monopoly behavior known as "product hopping". 

Product hopping refers to a strategy employed by original drug manufacturers to avoid or reduce competition from generic drugs, which mostly occurs shortly before the expiration of a patented drug and the entry of its generic counterpart and if applied inappropriately, could constitute an abuse of market dominance.

Factors for evaluation include whether the new patented drug represents a non-substantial improvement and whether the transition hinders or delays the entry of generics into the market, according to the guidelines.

"This is not about restricting the development of patented drugs but about regulating false innovation that fails to significantly improve a drug's efficacy, safety or utility," Zhou said.

Comprising seven chapters and 55 articles, the guidelines aim to provide detailed interpretations of monopolistic practices, enforcement principles and criteria for determining violations, offering a comprehensive framework to tackle anti-competitive behaviors in the pharmaceutical industry.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 国产欧美一级二级三级在线视频 | 久久久久欧美激情 | 久久综合婷婷香五月 | 综合一区二区三区 | 精品五月天 | 国产精品久久av | 久草最新| 久久免费视频一区 | 精品视频国产 | 99精品在线免费观看 | 国产一区二区三区在线看片 | 午夜在线视频观看 | 男女一进一出无遮挡黄 | 久久精品网 | 久久一er精这里有精品 | 午夜国产电影 | 成人午夜电影在线播放网站 | 精品无人乱码一区二区三区 | 国产美女的小嫩bbb图片 | 91.成人天堂一区 | 69性影院在线观看国产精品87 | 国产精品国产三级国产a | 巨大乳女人做爰视频在线 | 国产午夜精品久久久久小说 | 久久国产精品一区二区三区 | 欧美一区二区三区免费视频 | 青草视频网站在线观看 | 狠狠色欧美亚洲狠狠色五 | 免费观看av网站 | 久久亚洲春色中文字幕久久 | 国产成人91精品 | 国产一区在线播放 | 国产精品久久久免费视频 | 亚洲精选一区 | 国产精品小黄鸭一区二区三区 | 三A级做爰片免费观看国产电影 | 日韩电影中文字幕 | 久久久久久综合 | 欧美在线综合 | 欧美黄色一区 | 欧美日韩一区二区在线 |